Investment Analysts’ Upgrades for August, 13th (BKEAY, BSIG, CALA, CAPR, CARO, CCCGY, CCOZY, CCR, CDTX, CDXC)

Investment Analysts’ upgrades for Tuesday, August 13th:

Bank of East Asia (OTCMKTS:BKEAY) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Bank E Asia has dedicated itself to service on behalf of the people of Hong Kong and customers in China and overseas. BEA is the largest independent local bank in Hong Kong. BEA offers a full range of wholesale and retail banking services covering corporate banking, personal banking, investment banking and China services. Products ranging from deposits, foreign currency savings, mortgage loans, consumer loans, credit cards, Cyberbanking, Mandatory Provident Fund services, trade finance, syndicated loans, remittances and foreign exchange margin trading. “

Brightsphere Investment Group (NYSE:BSIG) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “BrightSphere Investment Group plc is a diversified multi-boutique asset management company. The Company focuses on equities and fixed income portfolios, as well as investments in timber and real estate sectors. BrightSphere Investment Group plc, formerly known as OM Asset Management plc, is based in London, United Kingdom. “

Calithera Biosciences (NASDAQ:CALA) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $4.50 price target on the stock. According to Zacks, “Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. It is focused on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The Company’s lead product candidate includes CB-839 which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. Calithera Biosciences, Inc. is headquartered in South San Francisco, California. “

Capricor Therapeutics (NASDAQ:CAPR) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $3.50 target price on the stock. According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “

Carolina Financial (NASDAQ:CARO) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Carolina Financial Corporation is the holding company of CresCom Bank. It operates through three reportable segments: Community Banking, Wholesale Mortgage Banking, and other. Its deposit products include checking accounts, commercial accounts, savings accounts, retirement accounts, and other time deposits. The company’s loan portfolio comprises loans to small and medium-sized businesses, residential and commercial construction and development loans, commercial real estate loans, residential mortgage loans, residential lot loans, home equity loans, and consumer loans. The company also offers mortgage banking services comprising correspondent lending and loan servicing; and cash management services. Carolina Financial Corporation is based in Charleston, South Carolina. “

CHINA COMMUNICA/ADR (OTCMKTS:CCCGY) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “China Railway Construction Corporation Limited is engaged in engineering construction while providing project contracting, survey, design and consultation, industrial manufacturing, exploitation of real estate, capital operation and logistics. The Company is also engaged in scientific research, planning, survey, design, constructing, superintending, operating and equipment manufacturing. CRCC designs and constructs plateau railway, high-speed railway, expressway, bridges, tunnels and urban track transportation projects. Its businesses are divided into four major segments, namely: construction operations; survey, design and consultancy operations; manufacturing operations; and other businesses, including real estate development and logistics services that relate to its main businesses. “

CHINA COAL ENER/ADR (OTCMKTS:CCOZY) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $8.75 price target on the stock. According to Zacks, “China Coal Energy Company Limited is engaged in integrating engineering and technological service businesses comprising of coal production, sales and trading. It deals in coal chemical, coal mining equipment manufacturing, pit mouth power generation, coal mine design etc. The main businesses of the Company are coking operations, coal mining equipment manufacturing and coal mine design and consultation. Coal business involves in production and distribution of steam coal and coking coal. Coking business provides metallurgy coke and forging coke. Coke mining equipment business offers hydraulic supports, scraper conveyors, loaders, boring machines, shearers and mining electrical motors, among others. China Coal Energy Company Limited is headquartered in Beijing, China. “

CONSOL Coal Resources (NYSE:CCR) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “CONSOL Coal Resources LP manages and develops active thermal coal operations. The company engages in underground mines and related infrastructure that produce high- BTU bituminuous thermal coal. It primarily sells its coal to electric utilities in the United States. CONSOL Coal Resources LP, formerly known as CNX Coal Resrcs, is based in Canonsburg, Pennsylvania. “

Cidara Therapeutics (NASDAQ:CDTX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $1.50 price target on the stock. According to Zacks, “Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California. “

Chromadex (NASDAQ:CDXC) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex’s core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, green, mass marketable products to its customers. The Company’s main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico. “

CNOOC (NYSE:CEO) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Cnooc Limited is a company that engages primarily in the exploration, development and production of crude oil and natural gas offshore China. We are the dominant producer of crude oil and natural gas and the only company permitted to conduct exploration and production activities with international oil and gas companies offshore China. “

Chesapeake Lodging Trust (NYSE:CHSP) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Chesapeake Lodging Trust is a real estate investment trust. It is a self-advised hotel investment company focused on investments in upper upscale hotels in business, airport, convention markets, and select-service hotels in urban settings or locations in the United States. “

Clinigen Group (OTCMKTS:CLIGF) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “

Receive News & Ratings for Bank of East Asia Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bank of East Asia Ltd and related companies with MarketBeat.com's FREE daily email newsletter.